Certain Lots of Taro-Zoledronic acid injection drug, used for osteoporosis and Paget's disease, recalled due to potential presence of particulate matter

Health Canada is advising Canadians that Taro Pharmaceuticals Inc. is recalling five lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because of the potential presence of particulate matter in the drug. Zoledronic acid is used to treat and prevent osteoporosis, as well as to treat Paget’s disease (i.e., a condition that causes bone deformities). If injected, the presence of particles could cause inflammation or irritation of veins that could cause blockage of blood vessels. In the most serious of cases it could cause lung damage, serious allergic reactions or formation of blood clots. All lots of the drug distributed by Taro Pharmaceuticals Inc. between August 1, 2018, and December 24, 2019, are affected by the recall. Health Canada is monitoring the recall, and should the Department become aware of additional safety information, it will take appropriate action and inform Canadians as necessary.